Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development, from pre-clinical through Phase III studies, to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. Genmab’s strategy is to balance risk by building a broad pipeline of products. Human antibodies are expected to be particularly useful in these conditions as they should lend themselves to long-term therapy without the risk of immune system rejection. In addition to the HuMax® products currently in pre-clinical and clinical studies, Genmab, in partnership with several international pharmaceutical and biotechnology companies, has numerous other disease targets, including several concerning infectious disease, under evaluation for our expanding product pipeline. Genmab is an international company with operations in Europe and the United States.
Genmab’s products are created using the most advanced human antibody technologies available. With access to the UltiMAb® system for generating the full range of human antibody isotypes, Genmab is able to rapidly produce high-affinity, human antibodies against almost any disease target. Genmab’s HuMax antibodies are 100 percent human, ready to be developed into therapeutic products without any further costly and time-consuming engineering. Previous generations of antibody products have typically contained mouse or other proteins, such antibodies have the potential to elicit allergic responses or other complications. Furthermore, Genmab’s high-affinity HuMax antibodies are often 100 to 1000 times better at finding and binding to their target than earlier generation antibodies.
Genmab’s clinical programs include HuMax-CD4® in Phase III for CTCL (cutaneous T-cell lymphoma) and Phase II for NCTCL (non-cutaneous T-cell lymphoma). HuMax-CD20™ is in Phase III for CLL and we are preparing both HuMax-CD20 in NHL and HuMax-EGFr™ for pivotal studies. HuMax-CD20 is also in Phase II for rheumatoid arthritis.
Genmab also maintains a large preclinical pipeline of more than ten products, including HuMax-HepC™ (Hepatitis C reinfection), HuMax-TAC™ (inflammation, autoimmune disorders and organ transplant rejection) and HuMax-CD38™ (multiple myeloma).
Genmab has assembled scientific, clinical, and regulatory teams with broad international experience to rapidly develop and test new therapeutic antibody products.
Genmab has a multi-pronged strategy for increasing the value of our business while reducing risk. Our goal is to maximize value in our products by retaining substantial commercial or profit sharing rights. We intend to develop these products ourselves and in collaboration with our existing and prospective partners using a combination of in-house clinical development and out-licensing as appropriate for each product. We pursue new strategic collaborations with pharmaceutical and biotechnology companies to support and broaden our pipeline. We believe maintaining a broad portfolio of products increases our opportunities for success.
Last Updated: 06-09-2006